- Home
- DHF vs MDWD Comparison
DHF vs MDWD Comparison
Compare DHF & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHF
- MDWD
- Stock Information
- Founded
- DHF 1998
- MDWD 2000
- Country
- DHF United States
- MDWD Israel
- Employees
- DHF N/A
- MDWD N/A
- Industry
- DHF Finance Companies
- MDWD Medicinal Chemicals and Botanical Products
- Sector
- DHF Finance
- MDWD Health Care
- Exchange
- DHF Nasdaq
- MDWD Nasdaq
- Market Cap
- DHF 188.4M
- MDWD 184.8M
- IPO Year
- DHF N/A
- MDWD 2014
- Fundamental
- Price
- DHF $2.58
- MDWD $18.99
- Analyst Decision
- DHF
- MDWD Strong Buy
- Analyst Count
- DHF 0
- MDWD 1
- Target Price
- DHF N/A
- MDWD $25.00
- AVG Volume (30 Days)
- DHF 451.1K
- MDWD 59.3K
- Earning Date
- DHF 01-01-0001
- MDWD 11-26-2024
- Dividend Yield
- DHF 7.65%
- MDWD N/A
- EPS Growth
- DHF N/A
- MDWD N/A
- EPS
- DHF N/A
- MDWD N/A
- Revenue
- DHF N/A
- MDWD $19,720,000.00
- Revenue This Year
- DHF N/A
- MDWD $10.37
- Revenue Next Year
- DHF N/A
- MDWD $26.36
- P/E Ratio
- DHF N/A
- MDWD N/A
- Revenue Growth
- DHF N/A
- MDWD N/A
- 52 Week Low
- DHF $2.06
- MDWD $11.04
- 52 Week High
- DHF $2.39
- MDWD $24.00
- Technical
- Relative Strength Index (RSI)
- DHF 49.54
- MDWD 57.54
- Support Level
- DHF $2.53
- MDWD $15.80
- Resistance Level
- DHF $2.62
- MDWD $18.25
- Average True Range (ATR)
- DHF 0.03
- MDWD 0.82
- MACD
- DHF 0.00
- MDWD 0.03
- Stochastic Oscillator
- DHF 61.11
- MDWD 96.56
About DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. It invests predominantly in fixed-income securities of below-investment-grade credit quality.
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.